128 related articles for article (PubMed ID: 36113407)
1. CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: Evidence from clinical practice.
D'Onofrio R; Caputo F; Prampolini F; Spallanzani A; Gelsomino F; Bettelli S; Manfredini S; Reggiani Bonetti L; Carotenuto P; Bocconi A; Dominici M; Luppi G; Salati M
Tumori; 2023 Aug; 109(4):387-393. PubMed ID: 36113407
[TBL] [Abstract][Full Text] [Related]
2. Plasma ctDNA RAS status selects patients for anti-EGFR treatment rechallenge in metastatic colorectal cancer: a meta-analysis.
Vlachou MS; Mauri D; Zarkavelis G; Ntellas P; Tagkas C; Gkoura S; Pentheroudakis G
Exp Oncol; 2021 Sep; 43(3):252-256. PubMed ID: 34591420
[TBL] [Abstract][Full Text] [Related]
3. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
[TBL] [Abstract][Full Text] [Related]
4. The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review.
Ciardiello D; Mauri G; Sartore-Bianchi A; Siena S; Zampino MG; Fazio N; Cervantes A
Cancer Treat Rev; 2024 Mar; 124():102683. PubMed ID: 38237253
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.
Sartore-Bianchi A; Pietrantonio F; Lonardi S; Mussolin B; Rua F; Crisafulli G; Bartolini A; Fenocchio E; Amatu A; Manca P; Bergamo F; Tosi F; Mauri G; Ambrosini M; Daniel F; Torri V; Vanzulli A; Regge D; Cappello G; Marchiò C; Berrino E; Sapino A; Marsoni S; Siena S; Bardelli A
Nat Med; 2022 Aug; 28(8):1612-1618. PubMed ID: 35915157
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
Martinelli E; Martini G; Famiglietti V; Troiani T; Napolitano S; Pietrantonio F; Ciardiello D; Terminiello M; Borrelli C; Vitiello PP; De Braud F; Morano F; Avallone A; Normanno N; Nappi A; Maiello E; Latiano T; Falcone A; Cremolini C; Rossini D; Santabarbara G; Pinto C; Santini D; Cardone C; Zanaletti N; Di Liello A; Renato D; Esposito L; Marrone F; Ciardiello F
JAMA Oncol; 2021 Oct; 7(10):1529-1535. PubMed ID: 34382998
[TBL] [Abstract][Full Text] [Related]
7. Clinical Validation of Plasma-Based Genotyping for
Aoki Y; Nakamura Y; Denda T; Ohta T; Esaki T; Shiozawa M; Yamaguchi K; Yamazaki K; Sunakawa Y; Kato T; Okano N; Taniguchi H; Sato T; Oki E; Nishina T; Komatsu Y; Matsuhashi N; Goto M; Yasui H; Ohtsubo K; Moriwaki T; Takahashi N; Horita Y; Boku S; Wakabayashi M; Ikeno T; Mitani R; Yuasa M; Yoshino T
JCO Precis Oncol; 2023 Jun; 7():e2200688. PubMed ID: 37343204
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials.
Martini G; Ciardiello D; Famiglietti V; Rossini D; Antoniotti C; Troiani T; Napolitano S; Esposito L; Latiano TP; Maiello E; Del Re M; Lonardi S; Aprile G; Santini D; Masi G; Avallone A; Normanno N; Pietrantonio F; Pinto C; Ciardiello F; Cremolini C; Martinelli E
Cancer Med; 2023 Apr; 12(8):9392-9400. PubMed ID: 36880426
[TBL] [Abstract][Full Text] [Related]
9.
Sunakawa Y; Nakamura M; Ishizaki M; Kataoka M; Satake H; Kitazono M; Yanagisawa H; Kawamoto Y; Kuramochi H; Ohori H; Nakamura M; Maeda F; Komeno C; Sonezaki T; Takeuchi M; Fujii M; Yoshino T; Tsuji A; Ichikawa W
JCO Precis Oncol; 2020 Nov; 4():898-911. PubMed ID: 35050760
[TBL] [Abstract][Full Text] [Related]
10. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival.
Ciardiello D; Famiglietti V; Napolitano S; Esposito L; Pietrantonio F; Avallone A; Maiello E; Cremolini C; Troiani T; Martinelli E; Ciardiello F; Martini G
Clin Colorectal Cancer; 2022 Jun; 21(2):141-148. PubMed ID: 35101346
[TBL] [Abstract][Full Text] [Related]
11. Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis.
Rossini D; Germani MM; Pagani F; Pellino A; Dell'Aquila E; Bensi M; Liscia N; Moretto R; Boccaccino A; Prisciandaro M; Manglaviti S; Schirripa M; Vivolo R; Scartozzi M; Santini D; Salvatore L; Pietrantonio F; Loupakis F; Falcone A; Cremolini C
Clin Colorectal Cancer; 2020 Sep; 19(3):191-199.e6. PubMed ID: 32466976
[TBL] [Abstract][Full Text] [Related]
12. Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry.
Chong LC; Hardingham JE; Townsend AR; Piantadosi C; Rico GT; Karapetis C; Padbury R; Maddern G; Roy A; Price TJ
Target Oncol; 2020 Dec; 15(6):751-757. PubMed ID: 33068283
[TBL] [Abstract][Full Text] [Related]
13. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
[TBL] [Abstract][Full Text] [Related]
14. Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study.
Vidal J; Fernández-Rodríguez MC; Casadevall D; García-Alfonso P; Páez D; Guix M; Alonso V; Cano MT; Santos C; Durán G; Elez E; Manzano JL; Garcia-Carbonero R; Ferreiro R; Losa F; Pineda E; Sastre J; Rivera F; Bellosillo B; Tabernero J; Aranda E; Salazar R; Montagut C;
Clin Cancer Res; 2023 Jan; 29(2):379-388. PubMed ID: 36074154
[TBL] [Abstract][Full Text] [Related]
15. Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11).
Sunakawa Y; Satake H; Usher J; Jaimes Y; Miyamoto Y; Nakamura M; Kataoka M; Shiozawa M; Takagane A; Terazawa T; Watanabe T; Ishiguro K; Tanaka C; Takeuchi M; Fujii M; Danenberg K; Danenberg PV; Lenz HJ; Sekikawa T; Ichikawa W
ESMO Open; 2022 Jun; 7(3):100512. PubMed ID: 35688061
[TBL] [Abstract][Full Text] [Related]
16. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.
Grasselli J; Elez E; Caratù G; Matito J; Santos C; Macarulla T; Vidal J; Garcia M; Viéitez JM; Paéz D; Falcó E; Lopez Lopez C; Aranda E; Jones F; Sikri V; Nuciforo P; Fasani R; Tabernero J; Montagut C; Azuara D; Dienstmann R; Salazar R; Vivancos A
Ann Oncol; 2017 Jun; 28(6):1294-1301. PubMed ID: 28368441
[TBL] [Abstract][Full Text] [Related]
17. Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer.
Sorah JD; Moore DT; Reilley MJ; Salem ME; Triglianos T; Sanoff HK; McRee AJ; Lee MS
Oncologist; 2022 Dec; 27(12):1006-e930. PubMed ID: 36288238
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials.
Ciardiello D; Napolitano S; Famiglietti V; Esposito L; De Falco V; Di Liello A; Avallone A; Maiello E; Pietrantonio F; Cremolini C; Zampino MG; Fazio N; Troiani T; Martinelli E; Ciardiello F; Martini G
Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046778
[TBL] [Abstract][Full Text] [Related]
19. KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR.
Pinheiro M; Peixoto A; Rocha P; Veiga I; Pinto C; Santos C; Pinto P; Guerra J; Escudeiro C; Barbosa A; Silva J; Teixeira MR
Int J Colorectal Dis; 2022 Apr; 37(4):895-905. PubMed ID: 35303157
[TBL] [Abstract][Full Text] [Related]
20. A Trial Protocol of Precision Medicine for Patients with RAS Wild Metastatic Colorectal Cancer Using Liquid Biopsy (RAS-liquid Study): A Prospective, Multicenter Observational Study.
Matsuda A; Yamada T; Takahashi T; Hirata K; Nagasaka T; Ishimaru K; Sakamoto K; Koda K; Ishikawa T; Ishida H; Matsuda K; Kuramochi H; Yoshida Y; Sonoda H; Yoshida H
J Anus Rectum Colon; 2022; 6(1):52-57. PubMed ID: 35128137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
